- GSK
- 20 January 2025 07:33:54
Source: Sharecast
The European Commission said that, when used alongside chemotherapy, Jemperli (otherwise known as dostarlimab) can now be used to treat people with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumours, which represent approximately 75% of patients diagnosed with endometrial cancer.
Hesham Abdullah, senior vice president and global head of oncology at GSK's R&D unit, said: "We're proud Jemperli continues to redefine the treatment landscape for patients."
The approval was based on results from part one of the RUBY phase III trial, which showed a median overall survival rate of 44.6 months for Jemperli plus chemotherapy, compared with 28.2 months for chemotherapy alone.
Commenting on the ruling, oncologist Dr Mansoor Raza Mirza, the principal investigator of the RUBY trial, said clinicians have been "waiting for years" for an immuno-oncology-based option to treat MMRp/MSS primary advanced or recurrent endometrial cancer.
"The expanded approval represents a significant advance that delivers on this hope," he said.